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A B S T R A C T
In this study, polymeric microneedle patches were fabricated by stereolithography, a 3D printing technique, for
the transdermal delivery of insulin. A biocompatible resin was photopolymerized to build pyramid and cone
microneedle designs followed by inkjet print coating of insulin formulations. Trehalose, mannitol and xylitol
were used as drug carriers with the aim to preserve insulin integrity and stability but also to facilitate rapid
release rates. Circular dichroism and Raman analysis demonstrated that all carriers maintained the native form
of insulin, with xylitol presenting the best performance. Franz cell release studies were used for in vitro de-
termination of insulin release rates in porcine skin. Insulin was released rapidly within 30min irrespectively of
the microneedle design. 3D printing was proved an eﬀective technology for the fabrication of biocompatible and
scalable microneedle patches.
1. Introduction
Over the last 20 years transdermal microneedles (MNs) have paved
the way for the delivery of various active substances across the skin
(Alkilani et al., 2015; Sanjay et al., 2017). These miniature devices are
used for the administration of active drug substances and vaccines,
including genetic material such as RNA and DNA (Chen et al., 2016).
MNs can pierce the skin in a painless way and through the penetration
of the stratum corneum the drug substance is released into the dermis.
The minimally invasive administration of MNs has shown to improve
systemic drug adsorption and thus bioavailability (Wermeling et al.,
2008). Ideally, they provide improved patient compliance as they do
not stimulate nerves associated with pain and can be self-administrated
(Kaushik et al., 2001). MNs are classiﬁed into four categories including
solid, coated, hollow, hydrogel – forming and dissolvable microneedles
usually made of metal, polysaccharides or polymeric materials (Ita,
2015).
Recent advances in skin delivery mediated by MNs involve the de-
velopment of polyvinylpyrrolidone (PVP) and trehalose dissolvable
MNs for the encapsulation of peptides. The MNs achieved rapid sys-
temic delivery by dissolving in the interstitial ﬂuid of the skin and re-
tained the antimicrobial activity of the peptide (Dillon et al., 2017). In
another study, MNs made of chitosan and beta-sodium glyceropho-
sphate showed eﬃcient delivery of levonorgestrel in vivo without
causing any skin irritation. The pharmacokinetic proﬁle of the drug,
presented similarities with the respective one of oral suspension, de-
monstrating that drug-loaded dissolving MN systems are an appealing
alternative to traditional levonorgestrel administration routes (Yao
et al., 2017). In another study, MNs were coated with 60 μg of a plasmid
DNA cocktail encoding the Leishmania infantum nucleosomal histones
H2A, H2B, H3 and H4 and their immunization capacity was compared
against subcutaneous or intradermal injection of the plasmid. The re-
sults demonstrated that MNs improved immunogenicity, but higher
plasmid doses might be required for better Leishmania control (Moreno
et al., 2017).
Signiﬁcant eﬀorts have been made in the skin delivery of insulin
analogs by using MNs in order to address the accuracy of the injections,
decrease leakage of insulin to the skin surface, and reduce pain caused
by repeated injections (Guo and Wang, 2017; Narayan, 2014). In a
recent study, MNs for insulin delivery, composed of modiﬁed alginate
and hyaluronate, were fabricated by micromoulding (Yu et al., 2017).
The optimized MNs showed good mechanical strength and piercing
capacity while insulin bioactivity was not aﬀected. In vivo studies de-
monstrated a sustained hypoglycaemic eﬀect with high relative phar-
macologic availability and relative bioavailability, compared to sub-
cutaneous injections. Clinical studies in diabetic Sprague – Dawley rats
demonstrated eﬀective hypoglycaemic control when insulin was re-
leased from calcium sulfate and gelatine biodegradable composite mi-
croneedle patches, showing that insulin is a suitable candidate for MN-
mediated transdermal delivery (Yu et al., 2017).
https://doi.org/10.1016/j.ijpharm.2018.03.031
Received 23 November 2017; Received in revised form 20 February 2018; Accepted 15 March 2018
⁎ Corresponding author.
E-mail address: D.Douroumis@gre.ac.uk (D. Douroumis).
International Journal of Pharmaceutics xxx (xxxx) xxx–xxx
0378-5173/ © 2018 Elsevier B.V. All rights reserved.
Please cite this article as: Pissinato Pere, C.P., International Journal of Pharmaceutics (2018), https://doi.org/10.1016/j.ijpharm.2018.03.031
However, there are several pitfalls in MN skin delivery, related to
the manufacturing process and materials used for the development of
MN patches. Micromoulding is the most common approach used for the
fabrication of dissolving and gel - forming MNs and involves a sequence
of time-consuming and diﬃcult to scale-up steps. On the other hand,
coating technologies do not always result in uniform, accurate and re-
producible active coated layers and fail to avoid drug deposition on the
MNs substrate. There are also serious concerns regarding the bio-
compatibility, skin irritation and even sterilization issues (McCrudden
et al., 2015) of the materials (e.g. silicon, polymers) used for MNs
fabrication as most of them are suitable for oral use but not approved
for skin delivery. The limited loading of active substances in most of
these MN technologies is another shortcoming for eﬃcient transdermal
delivery. More explicitly, coating techniques limit the drug amount that
can be loaded in the system to 1mg maximum (Kim et al., 2012) while
larger amounts (up to 33mg) have been successfully delivered by dis-
solving MNs (McCrudden et al., 2014).
3D printing or additive manufacturing is a family of technologies
that employ a virtual Computer Aided Design (CAD) model to create a
physical object through the consecutive creation of layers. It was
launched in 1980s (Kodama, 1981; Hull, 1984) and it has re-
volutionized the ﬁeld of pharmaceutical, biomedical and material sci-
ences due to the capabilities for rapid and cost-eﬀective prototyping of
complex structures (Pedde et al., 2017). 3D printing endows the pro-
totyping and fabrication process with versatility; objects are manu-
factured in a one-step fashion with high degrees of complexity and
reproducibility.
Among the various technologies that comprise 3D printing, photo-
polymerisation-based techniques enable the fabrication of structures
through the consecutive layer-wise polymerization of UV-sensitive
polymers, through a curing process named photopolymerization.
Stereolithography (SLA), Digital Light Processing (DLP) and Two-
Fig. 1. SEM images of 3D printed microneedle designs of: a) plain pyramid, b) plain cone, c) insulin coated pyramid and c) insulin coated cone.
Fig. 2. Inkjet coating process of 3D printed microneedles.
Table 1
Secondary structure prediction by CDSSTR using far-ultraviolet CD spectra.
Insulin Insulin:Xylitol 5:1 Insulin:Mannitol 5:1 Insulin:Trehalose 5:1
Alpha Helix 58% 57% 54% 53%
β-Sheet 7% 7% 10% 10%
Turn 10% 11% 11% 11%
Random coil 26% 26% 26% 26%
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Fig. 3. CD of insulin and insulin formulations.
Fig. 4. Raman spectra from 400 to 1800 cm−1 of pure insulin and insulin formulations.
Fig. 5. Force vs displacement curves for MN penetration in porcine skin.
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Photon-Polymerization (2PP) are among these technologies
(Economidou et al., 2018). In the ﬁeld of Transdermal Drug Delivery
(TDD), Gittard et al. employed a photopolymerisation-based printer
(DLP) to fabricate MNs of various geometries for wound healing ap-
plications, followed by pulse laser deposition of silver and zinc oxide
thin ﬁlms (Gittard et al., 2011). Similarly, Lu et al. incorporated Da-
carbazine (1–2%), a skin anticancer drug, into poly(propylene fuma-
rate)/drug blends followed by photopolymerization through a micro-
stereolithographic (DLP) apparatus that built the MN arrays (Lu et al.,
2015).
In this study, we employed SLA to fabricate MN arrays of diﬀerent
designs followed by inkjet printing of insulin – sugar ﬁlms. 3D printed
patches, featuring MN with cone and pyramid geometries, were made
using a Class 1 biocompatible resin with excellent mechanical strength
and piercing capacity. Mannitol, trehalose and xylitol, were used as
insulin carriers in order to preserve insulin activity prior to the appli-
cation of uniform and accurate “active” coating on the MN surface.
2. Materials and methods
Insulin solution from bovine pancreas (10mgmL−1) and trehalose
dihydrate were purchased from Sigma-Aldrich (Gillingham, UK), while
Xylisorb® 90 (Xylitol) and Pearlitol® (mannitol) were kindly donated by
Roquette Freres (France). The printing polymer was the biocompatible
Class I resin, Dental SG, procured by Formlabs. All solvents were of
analytical grades.
2.1. 3D printing of microneedles
Two diﬀerent MN designs, pyramid and cone, were developed using
appropriate engineering software (SolidWorks by Dassault Systems),
featuring square and circular cross-sections, respectively. The length of
all MNs was 1mm while the dimensions of the base cross-sections were
1× 1 mm for the pyramid and ø 1mm for the cone. The MNs were built
as attached to a solid 15× 15×1 mm substrate, forming patches of 48
MNs each. The arrays were fabricated using a Form 2 stereolithography
(SLA) printer by Formlabs, with high resolution capabilities (25 and
140 µm for z and x axes, respectively). To obtain higher mechanical
properties, the MN arrays, after being washed in isopropyl alcohol to
remove excess resin, were cured under ultraviolet radiation for 60min
at 40 °C (MeccatroniCore BB Cure Dental station).
2.2. Inkjet printing of insulin formulations microneedles
The insulin solutions were printed onto each MN surface in the form
of ﬁne droplets using an inkjet printer (NanoPlotter II, Gesim,
Germany) through a piezo-driven dispenser (PicPip 300). All MN arrays
were positioned at 45° relative to the dispenser and for each coating
cycle, 10 dots of 2 droplets of a coating formulation were dispensed
longitudinally to the axis of each MN. The process was repeated for 46
jetting cycles resulting in 10 UI (350 µg) of insulin per array. Solvent
(de-ionised water) was evaporated to produce uniform and re-
producible solid thin ﬁlms on the MNs after 24 h of incubation at room
temperature. For the purposes of this study three coating formulations
were used, consisting of insulin:xylitol (5:1 wt/wt), insulin: mannitol
(5:1 wt/wt) and insulin:trehalose (5:1 wt/wt) as 2% solid content.
2.3. Scanning electron microscopy (SEM)
The MN arrays were mounted onto aluminium stubs using a double-
sided carbon adhesive tape (Agar scientiﬁc, UK). Each MN array was
examined by SEM (Hitachi SU 8030, Japan) using a low accelerating
voltage (1.0 kV). A low accelerating voltage was used to avoid electrical
charges on the MNs. The images of the MNs were captured digitally
from a ﬁxed working distance (11.6mm) using diﬀerent magniﬁcations
(30, 80, 110 or 120×).
2.4. Circular Dicroism (CD) analysis
The formulations were diluted to 1.0mgmL−1 in deionized water
and the spectra were recorded at 20 °C between 190 and 260 nm by CD
(Chirascan, Applied Photophysics, UK) using a 0.1mm polarization
certiﬁed quartz cell (Hellma). Spectra were recorded using a step size of
1 nm, a bandwidth of 1 nm and an acquisition time of 1 s. Four scans
were recorded for each sample, averaged and a corresponding spectrum
of water was subtracted from each spectrum. For estimation of the
secondary structural composition of insulin, the CD spectra were eval-
uated using CDSSTR method (Sreerama and Woody, 2000).
2.5. Raman analysis
The ﬁlms of the formulations and their respective components were
analysed using Raman spectroscopy (Jobin Yvon LabRam I) with a laser
of 532 nm wavelength coupled with an optical microscope with 50×
objective.
2.6. Penetration of MN in porcine skin
The necessary force required to pierce the skin has been found to be
straightforwardly aﬀected by the geometry of the MNs (Davis et al.,
2004). In this study, to determine the eﬀect of needle shape on the force
required for skin penetration, piercing tests using porcine skin were
conducted. In order to have a frame of reference with respective lit-
erature, metallic MN arrays were tested as well, the fabrication and
physical characteristics of which, are described elsewhere (Ross et al.,
2015). A texture analyser was employed, and the MN array was
mounted on the moving probe using double-sided adhesive tape. Prior
to testing, the porcine skin samples were placed in waxed petri dishes.
Continuous force and displacement measurements were recorded to
identify the point of needle insertion. The speed of the moving probe
was 0.01mm/s.
2.7. Skin preparation for in-vitro MN testing
Full thickness abdominal porcine skin was collected from a local
Fig. 6. Maximum forces for MN penetration in porcine skin.
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slaughterhouse (Forge Farm Ltd, Kent, UK). The abdominal hair was
shaved using a razor blade. The collected skin was stored at 4 °C until it
was used. The fatty tissue below the abdominal area of porcine skin was
removed with a scalpel and then pinned onto polystyrene block and
wiped with 70% ethanol. The skin was then cut at 750 μm by applying
the dermatome at an angle of± 45° (Padgett dermatome, Integra
LifeTMSciences Corporation USA). The thickness of the skin was mea-
sured by using a calliper and the tissue disks of the required dimensions
were cut for the Franz diﬀusion cells using a scalpel. The skin tissue was
placed onto ﬁlter paper soaked in a small amount of saline phosphate
buﬀer (pH 7.4) for 2 h.
2.8. In vitro release of insulin coated MNs
Release studies of insulin were undertaken in abdominal porcine
skin using Franz diﬀusion cells (PermeGear, Inc., PA, USA). Skin sam-
ples with a total diﬀusion area of 1.1 cm2 were then placed in phos-
phate buﬀered saline (PBS; pH 7.4) for 1 h before the in vitro studies.
The MN arrays were inserted into the abdominal porcine skin samples
for 30 s using manual ﬁnger pressure. A skin pierced MN array was
mounted onto the donor compartment of a Franz diﬀusion cell. The
temperature of the Franz cells was maintained at 37 °C using an auto-
mated water bath (Thermo Fisher Scientiﬁc, Newington, USA). Sample
fractions (6–6.5mL/h) were collected using an auto-sampler (FC 204
fraction collector, Gilson, USA) attached to the Franz diﬀusion cells.
Statistical analysis for the drug release was performed by using a Mann-
Whitney nonparametric test (InStat, GraphPad Software Inc., San
Diego, CA, USA), where samples are considered to be statistically sig-
niﬁcant at p < 0.05.
2.9. HPLC analysis
The amount of insulin collected from the receptor ﬂuid was de-
termined by High-Performance Liquid Chromatography (HPLC; Agilent
Technologies, 1200 series, Cheshire, UK) equipped with a Phenomenex
Jupiter 5u c18 300 Å, LC Column (250× 4.60mm, particle size 5 μm,
Macclesﬁeld, UK). The mobile phase consisted of water with 0.1% TFA
and acetonitrile with 0.1% TFA (66:34v/v), with a 1mLmin−1 ﬂow
Fig. 7. Dissolution proﬁles of insulin 3D printed cone and pyramid shaped microneedles.
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rate. The column was equilibrated at 35 °C, the injection volume was 20
μL and the eluent was analysed with a UV detector at 214 nm. The
results were integrated using Chemstation® software and the samples
analysed in triplicates.
3. Results and discussion
MN arrays with cone- and pyramid-shaped needles were success-
fully printed using an additive manufacturing technique known as
stereolithography. The SLA processes a Class I biocompatible resin to
build up structures in a layer – by – layer manner from CAD models.
Dental SG resin is one of the few commercially available, biocompa-
tible, FDA certiﬁed polymers that are compatible with stereo-
lithography printers and the only Class I compatible with the Form 2
system. After printing, the MN arrays were cured using a light source –
UV laser to harden the plastic MN patches through a photo-
polymerization process resulting in improved mechanical properties. As
shown in Fig. 1 SLA produced two diﬀerent designs of pyramid (6× 8)
and cone-shaped (6× 8) MN patches with 1000 μm height, 1000 μm
width and 1.85mm interspacing distance (measured from tip-to-tip). In
Fig. 1a and b the build layers of both MN designs appear highly con-
sistent and reproducible. The high resolution of the printer permitted
the reproducible fabrication of arrays in excellent detail, leading to the
formation of sharp needle tips that favour the skin insertion. The low
cost of the printing material and the fast production speed renders SLA
an attractive process for MN fabrication. Quantitively, the currently
available commercial SLA apparatuses have a limited print volume and
the existing print volume (145×145×175mm) allows the manu-
facturing of up to 49 MN arrays within 2 h according to the dimensions
and methodology described. Upscaling of the process at a manu-
facturing scale depends on the introduction of printers with larger print
volumes. However, considering the low cost of these printers and the
short fabrication time, parallel printings in multiple printers can gen-
erate a great number of arrays fast and accurately.
Inkjet printing was then employed to apply coatings of insulin and
sugar solutions through a piezoelectric dispenser. This 2D printing ap-
proach has been previously used for coating of metal MNs (Ross et al.,
2015; Uddin et al., 2015) where by optimizing the applied voltage (mV)
and the pulse duration (ms) droplets of 300 pL volume with consistent
particle size of 100–110 μm as observed by the printer’s stroboscope,
were produced. The dispenser’s tip (50 μm) was kept close to the mi-
croneedle surface to avoid losses of the coating material (Fig. 2). Fig. 1c
and d shows the morphologically excellent coatings on the MN surface
without the presence of any satellite droplets on the substrate. In ad-
dition, the inkjet printing led to the formation of uniform layers with
high precision and reproducibility without the creation of bulky coat-
ings observed in conventional techniques such as dip coating.
The coating formulations consisted of insulin solutions of two al-
cohol sugars (xylitol, mannitol) and a disaccharide (trehalose) speciﬁ-
cally selected as drug carries. The selection of those excipients was
twofold, ﬁrstly because they favour and enhance insulin stability in
solid state and secondly, we anticipated a rapid coating dissolution
immediately after the MN piercing (Yong et al., 2009; Kim et al., 2009;
Schiﬀter et al., 2010).
3.1. Circular dichroism
Circular dichroism (CD) is a well-known spectroscopic technique
used to study the secondary structure of proteins and polypeptides in a
solution. In order to investigate the eﬀect of diﬀerent sugars on the
structure of insulin, CD experiments were carried out. The secondary
structure of insulin in all samples was also estimated by the CDSSTR
method (Sreerama and Woody, 2000) and it is quantitatively sum-
marized in Table 1.
In Fig. 3 all far-UV CD spectra of insulin and insulin-sugar for-
mulations showed two negative minima around 210 and 225 nm,
commonly associated with predominant features of α-helices structure
which is in close agreement with the spectra already reported in lit-
erature (Ettinger and Timasheﬀ, 1971; Sarmento et al., 2007; Yong
et al., 2009; Andrade et al., 2015). Also, the secondary structure of pure
insulin in solution estimated by CDSSTR method, agrees well with that
obtained by others (Melberg and Johnson 1990; Yong et al. 2009). The
spectra of insulin-mannitol and insulin-trehalose show a slight decrease
in the absolute intensities at 210 and 225 nm which can indicate
changes in the ratio of α-helix and β-sheet content. According to the
secondary structure estimation, these changes do indicate a decrease in
α-helix content of 4 and 5% for mannitol and trehalose formulations,
respectively, with a simultaneously increase of 4% in the β-sheet. Al-
though, similar eﬀect of trehalose on α-helix content was reported by
Yong et al. (2009), the reason for this is still unclear and further re-
search is needed.
Among the tested sugars, xylitol presented the best capability to
maintain insulin in its native form with almost the same amount of α-
helix content. Regarding the stability and storage requirements, insulin
coated MN arrays where placed for stability studies at 2–8 °C for
30 days. The stored samples were further examined by CD and no
changes on the spectra where observed compared to the freshly coated
MNs (data not shown). These ﬁndings suggest that coating formulations
provide eﬃcient insulin protection according to regulatory require-
ments.
3.2. Raman spectroscopy
Raman spectroscopy has been widely used to study possible changes
in chemical composition as well to study important information about
protein conformation.
In this study, the spectrum of native insulin, Fig. 4, shows a strong
amide I band at 1661 cm−1 and a shoulder near 1682 cm−1 (CO
stretching with some contribution from the stretching of CN groups and
CCN deformations) which are indicative of α-helix structure and
random coil form, respectively, being in accordance with Yu et al.
(1972).
All insulin formulations spectra display a similar band shape to the
native insulin, assigning the α-helix structure. However, insulin-xylitol
and insulin-mannitol formulation display a shift towards greater fre-
quency, 1663 cm−1 and 1662 cm−1, respectively, and insulin-trehalose
was shifted to lower frequency, at 1658 cm−1. Furthermore, for man-
nitol formulation, an increase in the amide I peak absorbance was seen,
while a pronounced decrease was noted for the trehalose one. Those
changes might be due to the diﬀerent eﬀect of each sugar on the vi-
brational spectra of insulin as well as on the intra- and inter-chain
couplings between the adjacent peptide units as stated by Carpenter
and Crowe (1989) and Souillac et al. (2002).
Characteristic peaks of sugars were not found in Raman spectra due
to the fact that insulin is more concentrated in the formulation ﬁlms
compared to the carbohydrate ﬁlms. X-ray diﬀraction (XRD) analysis
(data not shown) suggested that the sugars were amorphous and
therefore it is likely to present a weak Raman spectrum. It has also been
suggested that there is also hydrogen bond between the sugar and the
dried protein as reported by Carpenter and Crowe (1989). This inter-
action is known as water-replacement mechanism and it is responsible
for preventing protein denaturation (Timasheﬀ, 1993) by replacing
water molecules with other hydrogen bond reducing then the prob-
ability of protein aggregation during the drying process (Souillac et al.,
2002). Therefore, the developed formulations have good capability to
maintain insulin molecule in its native form with high amounts of α-
helix content which is essential for its biological activity.
3.3. Penetration of MN in porcine skin
The polymeric arrays featuring diﬀerent MN shapes along with the
metallic ones were inserted in porcine skin samples using a texture
C.P.P. Pere et al. International Journal of Pharmaceutics xxx (xxxx) xxx–xxx
6
analyser. All MN designs successfully pierced the skin and no MN
failure was reported. Force against displacement data were con-
tinuously recorded throughout the penetration and the data are shown
in Fig. 5.
The sharp drop of the load corresponds to the insertion of the MN
into the skin (Davis et al., 2004). Prior to that event, all curves present
an initial linear portion (displacement < 0.3mm). The slope then
change constantly as the MN continues to penetrate the skin revealing a
non-linear connection between the developed forces and the penetra-
tion depth.
This behaviour could be attributed to the viscoelastic nature of the
skin tissue, however indentation studies by Pailler-Mattei et al. (2008)
proposed the neglecting of the viscous part and the consideration of the
skin as an elastic material in the load range of 0–20 N. Considering that
all the measurements are well below the 20 N margin, a linear con-
nection between force and displacement throughout the test should be
expected. The divergence from linearity shows that the needle pene-
tration of the skin starts earlier than the sharp drop of load. The load
increases as the needle goes deeper through the skin until a threshold
force is reached and insertion becomes abrupt. These ﬁndings are in
accordance with the work from Gittard et al. (2013) that concluded that
MN penetration should be viewed as a series of sequential penetrations
until a maximum force is applied, rather than a single event. The
threshold load indicates that the MN insertion is successful, and the
respective values are depicted in Fig. 6.
Regarding the diﬀerent designs and apart from the metallic MN that
require the maximum threshold force for penetration, the cone design
requires the least force to penetrate the porcine skin. Since both designs
are dimensionally similar, the variation of the maximum load required
for penetration can be attributed to the diﬀerence of the MN-to-skin
contact area between the two designs. Indeed, Eq. (1) yields a total
contact surface for the cone design, of 1.76mm2 per needle. On the
other hand, the lateral surface for pyramid is found to be 2.24mm2 per
needle, from Eq. (2).
= +S πr h rcone 2 2 (1)
where: r is the base radius and h the height of the MN.
= + + +S l w h w l h
2 2pyramid
2 2
2
2
(2)
where: l is the length of the base, w the width of the base, and h the
height of the MN.
The 21% diﬀerence in area between the two designs indicates that
the frictional forces after initial penetration until the threshold force in
reached, are greater for the pyramid needles. As a result, greater loads
are required to achieve further penetration through the skin.
3.4. Insulin release studies
In vitro insulin release studies were conducted using dermatomed
porcine skin through Franz diﬀusion cells. The alcohol sugars (man-
nitol, xylitol) and the disaccharide sugar (trehalose) provided excellent
coatings on the MN surface and due to their hydrophilic nature were
expected to provide rapid release rates. Indeed, as shown in Fig. 7a and
b the observed insulin release rates in the ﬁrst 2 min varied from 63 to
69% and from 57 to 64% for the pyramid and cone-shaped 3D micro-
needles, respectively. After 20min more than 80% of insulin was de-
tected in the receptor’s compartment and 90–95% in 30min. Further-
more, the release proﬁles were almost identical for all carriers and no
statistical diﬀerence was observed for each MN design (two-tail
p= 0.0026). The rapid insulin proﬁles were attributed to the extremely
high hydration rates of the alcohol sugars and the disaccharide re-
spectively, that take place within the porcine skin micro-cavities cre-
ated upon the MN piercing.
4. Conclusions
A 3D printing stereolithographic technique was introduced for the
fabrication of microneedle designs for insulin transdermal delivery. SLA
facilitated the printing of high quality MNs with various designs. Insulin
formulations with mannitol, trehalose and xylitol were deposited on the
MN surface using inkjet printing to provide accurate and reproducible
active coating layers. All carriers were found to preserve insulin in-
tegrity, namely the α-helix and β-Sheet, with xylitol presenting the
foremost performance. Franz cell diﬀusion studies revealed rapid in-
sulin release rates within 30min. In conclusion, it has been demon-
strated that 3D printing can be eﬃciently used for the fabrication of
microneedles for TDD.
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